New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Take the survey

›ETF Issuers›Defiance ETFs›ASD

ASD

Defiance Autism Impact ETF

Passive ETF Equity Theme: Tomorrow's Treatments

Not rated

The ASD Exchange Traded Fund (ETF) is provided by Defiance ETFs. It is built to track an index: VettaFi Autism Impact Index. The ASD ETF provides physical exposure, so by buying it you actually own parts of all the 37 underlying holdings. This share class generates a stream of income by distributing dividends.

$27.22

+$0.29 (+1.08%) yesterday

1:30 PM 07/21/26 Closed

1D price range

$26.95$27.22

52W price range

$24.61$27.66

YTD Perf.

+8.83%

YTD Flows

Annualized volatility

Fund AuM

€1.2M

Share class AuM

€1.2M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US2689613311

TER

0.79%

Inception date

5/29/2026

Issuer

Defiance ETFs

Benchmark

VettaFi Autism Impact Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
XDNA iShares Genomics Immunology and Healthcare Index ETF	+0.25%
IDNA iShares Genomics Immunology and Healthcare ETF	+0.16%
PJP Invesco Dynamic Pharmaceuticals ETF	+3.42%
2B78 iShares Healthcare Innovation UCITS ETF	+0.07%
LIV Smart Healthcare Innovation ETF	-2.47%
FOHW Franklin Future of Health and Wellness UCITS ETF	+1.35%
SBIO ALPS Medical Breakthroughs ETF	-0.09%
CANC Tema Oncology ETF	+0.75%
BBP Virtus LifeSci Biotech Products ETF	+0.52%
OZEM Roundhill GLP-1 & Weight Loss ETF	+0.58%
HRTS Tema GLP-1, Obesity & Cardiometabolic ETF	+0.86%
BBC Virtus LifeSci Biotech Clinical Trials ETF	-0.28%
MEDX Horizon Kinetics Medical ETF	+1.13%
THNR Amplify Weight Loss Drug & Treatment ETF	+1.36%

API

PerformanceJun 30, 2026 - Jul 21, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 06/30/26

Healthcare

82.88%

Consumer Non-Cyclicals

12.26%

Unavailable

4.86%

Latest ASD news

No content available for this fund

FAQ about ASD

ASD is a Passive ETF. This ETF provides exposure to Equally Weighted Equities.

ASD tracks the VettaFi Autism Impact Index - USD, through a full replication replication method.

ASD carries a total expense ratio (TER) of 0.79%, indicating the annual cost for holding the fund.

ASD was introduced to the market on May 29, 2026. It trades on United States

Defiance Autism Impact ETF, ASD, is provided by Defiance ETFs. Learn more about Defiance ETFs here.

ASD oversees €1.2M in assets as of July 21, 2026.

ASD follows a distributing dividend policy, meaning it pays out income to investors.

As of June 30, 2026, ASD has significant geographic allocations in USA, Japan and Switzerland.

As of June 30, 2026, ASD focuses largely on Healthcare and Consumer Non-Cyclicals.

As of June 30, 2026, ASD holds 37 positions in its portfolio, with 41.30% of assets concentrated in its top 15 holdings.

As of June 30, 2026, ASD top three holdings include Otsuka Holdings Co., Ltd., Lifestance Health Group, Inc. and ACADIA Pharmaceuticals, Inc..

The base currency of ASD is USD.

Top 10 holdings

Data as of 06/30/26

Otsuka Holdings Co., Ltd.

3.03%

Lifestance Health Group, Inc.

2.98%

ACADIA Pharmaceuticals, Inc.

2.95%

AbbVie, Inc.

2.79%

Revvity, Inc.

2.78%

Acadia Healthcare Co., Inc.

2.75%

Repligen Corp.

2.75%

MapLight Therapeutics, Inc.

2.73%

BrightSpring Health Services, Inc.

2.73%

Bright Horizons Family Solutions, Inc.

2.68%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

The ETF Industry Is Evolving Fast

Defiance Autism Impact ETF

FAQ about ASD

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US